{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"description":"Dose limiting toxities defined as: grade 3 thrombocytopenia, grade 4 anemia and neutropenia, grade \\>/= nonhematologic toxicity, and failure to recover from toxicites to be eligible for retreatment in 2 weeks of the last dose of either drug. Also grade 3 nonhematologic toxicities only if they wre refractory to maxiaml medical therapy.\n\nMTD defined as dose at which fewer than one-third of patients experienced a DLT\n\nOutcome measure defines number of participants who had a defined dose limiting toxicity.","groups":[{"description":"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (50mg). Every 28 days until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 1 - 50mg"},{"description":"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (25mg). Every 28 days until disease progression or unacceptable toxicity.","id":"OG001","title":"Phase 1 - 25 mg"},{"description":"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (15mg). Every 28 days until disease progression or unacceptable toxicity.","id":"OG002","title":"Phase 1 - 15mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"first 4 weeks of treatment","title":"Safety/Dose Limiting Toxities Phase I","type":"PRIMARY","unitOfMeasure":"participants"}